CA2344246A1
(en)
*
|
1998-09-17 |
2000-03-23 |
Akesis Pharmaceuticals, Inc. |
Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
|
US6376549B1
(en)
*
|
1998-09-17 |
2002-04-23 |
Akesis Pharmaceuticals, Inc. |
Metforimin-containing compositions for the treatment of diabetes
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
WO2001034594A1
(en)
*
|
1999-11-12 |
2001-05-17 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
|
US20040152745A1
(en)
*
|
1999-11-12 |
2004-08-05 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
|
GB9928330D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
SG149676A1
(en)
*
|
1999-12-23 |
2009-02-27 |
Novartis Ag |
Use of hypoglycemic agent for treating impaired glucose metabolism
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
CN1977842A
(zh)
|
2000-01-21 |
2007-06-13 |
诺瓦提斯公司 |
含有二肽基肽酶-iv抑制剂和抗糖尿病药物的联合形式
|
JP2003520849A
(ja)
*
|
2000-01-24 |
2003-07-08 |
ノボ ノルディスク アクティーゼルスカブ |
酵素dpp−ivの阻害剤であるn−置換2−シアノピロールおよび−ピロリン
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
MXPA02012272A
(es)
|
2000-07-04 |
2003-04-25 |
Novo Nordisk As |
Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
US20060089389A1
(en)
*
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
AU2002213925A1
(en)
|
2000-09-18 |
2002-03-26 |
Osteometer Biotech As |
Use of glp-1 and flp-2 peptides for treatment of bone disorders
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
NZ525630A
(en)
|
2000-10-06 |
2004-10-29 |
Tanabe Seiyaku Co |
Nitrogen-containing 5-membered ring compound used as dipeptidylpeptidase IV (DPPIV) inhibitor
|
TWI243162B
(en)
*
|
2000-11-10 |
2005-11-11 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
UA74023C2
(en)
*
|
2000-11-10 |
2005-10-17 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
WO2002051836A1
(fr)
*
|
2000-12-27 |
2002-07-04 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de dipeptidyl peptidase iv
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
US7098239B2
(en)
|
2001-06-20 |
2006-08-29 |
Merck & Co., Inc |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
JP2005500308A
(ja)
|
2001-06-20 |
2005-01-06 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤
|
DE60221983T2
(de)
|
2001-06-27 |
2008-05-15 |
Smithkline Beecham Corp. |
Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
|
DE60223920T2
(de)
*
|
2001-06-27 |
2008-11-13 |
Smithkline Beecham Corp. |
Pyrrolidine als dipeptidyl-peptidase-inhibitoren
|
DE60235212D1
(de)
|
2001-06-27 |
2010-03-11 |
Smithkline Beecham Corp |
Fluoropyrrolidine als Dipeptidylpeptidasehemmer
|
US6709651B2
(en)
*
|
2001-07-03 |
2004-03-23 |
B.M.R.A. Corporation B.V. |
Treatment of substance P-related disorders
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
WO2003038123A2
(en)
*
|
2001-10-31 |
2003-05-08 |
Novartis Ag |
Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
US20030135663A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Sun Microsystems, Inc. |
Method, system, and program for including device parameters from a device driver in a configuration file
|
CA2474460C
(en)
|
2002-02-13 |
2009-12-22 |
F. Hoffmann-La Roche Ag |
Pyridine- and quinoline-derivatives
|
PL371678A1
(en)
|
2002-02-13 |
2005-06-27 |
F.Hoffmann-La Roche Ag |
Novel pyridin- and pyrimidin-derivatives
|
EP1338595B1
(en)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Xanthine derivatives as DPP-IV inhibitors
|
DE60316416T2
(de)
*
|
2002-03-25 |
2008-06-26 |
Merck & Co., Inc. |
Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
|
CN101273987A
(zh)
*
|
2002-06-03 |
2008-10-01 |
诺瓦提斯公司 |
取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
|
US6710040B1
(en)
*
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
JP2004026678A
(ja)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
2型糖尿病治療剤
|
WO2004007446A1
(ja)
*
|
2002-07-10 |
2004-01-22 |
Yamanouchi Pharmaceutical Co., Ltd. |
新規なアゼチジン誘導体又はその塩
|
DE60330485D1
(de)
*
|
2002-07-15 |
2010-01-21 |
Merck & Co Inc |
Zur behandlung von diabetes
|
TW200401635A
(en)
*
|
2002-07-23 |
2004-02-01 |
Yamanouchi Pharma Co Ltd |
2-Cyano-4-fluoropyrrolidine derivative or salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1560811B9
(en)
*
|
2002-09-19 |
2008-03-05 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
|
CA2499586A1
(en)
|
2002-10-07 |
2004-04-22 |
Merck & Co., Inc. |
Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
|
PT1556362E
(pt)
*
|
2002-10-18 |
2008-06-16 |
Merck & Co Inc |
Compostos beta-amino heterocíclicos inibidores da dipeptidil peptidase para o tratamento ou prevenção da diabetes
|
US7157490B2
(en)
|
2002-11-07 |
2007-01-02 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JP2006510630A
(ja)
*
|
2002-12-04 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
|
US20060052382A1
(en)
*
|
2002-12-20 |
2006-03-09 |
Duffy Joseph L |
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
EP1599468B1
(en)
|
2003-01-14 |
2007-10-03 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US7265128B2
(en)
*
|
2003-01-17 |
2007-09-04 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
AU2004210149A1
(en)
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7550590B2
(en)
|
2003-03-25 |
2009-06-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
GB0308854D0
(en)
*
|
2003-04-16 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
PE20050021A1
(es)
*
|
2003-04-16 |
2005-03-15 |
Novartis Ag |
Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
|
EP1625122A1
(en)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
CN1787823A
(zh)
|
2003-05-14 |
2006-06-14 |
麦克公司 |
作为二肽基肽酶抑制剂用于治疗或预防糖尿病的3-氨基-4-苯基丁酸衍生物
|
EP1635818B1
(en)
|
2003-06-06 |
2010-04-07 |
Merck Sharp & Dohme Corp. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
WO2004112701A2
(en)
*
|
2003-06-17 |
2004-12-29 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
CA2529443C
(en)
|
2003-06-20 |
2012-06-05 |
F. Hoffmann-La Roche Ag |
Pyrido[2,1-a]-isoquinoline derivatives as dpp-iv inhibitors
|
BRPI0411509A
(pt)
|
2003-06-20 |
2006-07-25 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
|
WO2005011581A2
(en)
|
2003-07-31 |
2005-02-10 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
BRPI0413452A
(pt)
|
2003-08-13 |
2006-10-17 |
Takeda Pharmaceutical |
composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
WO2005025554A2
(en)
*
|
2003-09-09 |
2005-03-24 |
Japan Tobacco Inc. |
Dipeptidyl peptidase iv inhibitor
|
WO2005033099A2
(en)
*
|
2003-10-03 |
2005-04-14 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
|
US20050137142A1
(en)
*
|
2003-11-03 |
2005-06-23 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
AU2004286857A1
(en)
*
|
2003-11-04 |
2005-05-19 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
TWI337078B
(en)
*
|
2003-11-12 |
2011-02-11 |
Phenomix Corp |
Heterocyclic boronic acid compounds
|
EP2839832A3
(en)
*
|
2003-11-17 |
2015-06-24 |
Novartis AG |
Use of dipeptidyl peptidase IV inhibitors
|
SI1715893T1
(sl)
*
|
2004-01-20 |
2009-12-31 |
Novartis Pharma Ag |
Direktna kompresijska formulacija in postopek
|
SI1712547T1
(sl)
*
|
2004-02-05 |
2012-04-30 |
Kyorin Seiyaku Kk |
Bicikloestrski derivat
|
CA2554378A1
(en)
*
|
2004-02-18 |
2005-08-25 |
Kyorin Pharmaceutical Co., Ltd. |
Bicycloamide derivative
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US20090017015A1
(en)
*
|
2004-02-20 |
2009-01-15 |
Thomas Edward Hughes |
Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
|
US7514571B2
(en)
*
|
2004-02-27 |
2009-04-07 |
Kyorin Pharmaceutical Co., Ltd. |
Bicyclo derivative
|
AU2005221678B2
(en)
*
|
2004-03-09 |
2008-10-09 |
National Health Research Institutes |
Pyrrolidine compounds
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
AU2004318013B8
(en)
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
TW200604167A
(en)
*
|
2004-04-27 |
2006-02-01 |
Astellas Pharma Inc |
Pyrrolidine derivatives
|
US7687492B2
(en)
|
2004-05-04 |
2010-03-30 |
Merck Sharp & Dohme Corp. |
1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7671073B2
(en)
*
|
2004-05-18 |
2010-03-02 |
Merck Sharp & Dohme Corp. |
Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
WO2005117861A1
(en)
*
|
2004-06-04 |
2005-12-15 |
Novartis Ag |
Use of organic compounds
|
US7687638B2
(en)
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2006017292A1
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Constrained cyano compounds
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
JP2008507541A
(ja)
*
|
2004-07-23 |
2008-03-13 |
ロイヤルティ,スーザン・マリー |
ペプチダーゼ阻害剤
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
AR050615A1
(es)
*
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
EP1799639B1
(en)
*
|
2004-10-12 |
2013-09-04 |
Glenmark Pharmaceuticals S.A. |
Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
|
US20090253752A1
(en)
*
|
2004-10-25 |
2009-10-08 |
Bryan Burkey |
Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
CA2590957A1
(en)
|
2004-12-20 |
2006-06-29 |
Markus Boehringer |
4-aminopiperidine derivatives
|
EP2805953B1
(en)
|
2004-12-21 |
2016-03-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
GT200600008A
(es)
*
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
WO2006090244A1
(en)
*
|
2005-02-22 |
2006-08-31 |
Glenmark Pharmaceuticals S.A. |
New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
ZA200708179B
(en)
*
|
2005-04-22 |
2009-12-30 |
Alantos Pharmaceuticals Holding Inc |
Dipeptidyl peptidase-IV inhibitors
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
WO2006133160A2
(en)
|
2005-06-06 |
2006-12-14 |
Georgetown University |
Compositions and methods for lipo modeling
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
US20090149504A1
(en)
*
|
2005-06-17 |
2009-06-11 |
Aurigene Discovery Technologies Limited |
Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors
|
BRPI0613735A2
(pt)
*
|
2005-07-12 |
2011-02-01 |
Novartis Ag |
combinação de compostos orgánicos
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
JP2009503108A
(ja)
*
|
2005-08-04 |
2009-01-29 |
ノバルティス アクチエンゲゼルシャフト |
ビルダグリプチン塩
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
WO2007033350A1
(en)
|
2005-09-14 |
2007-03-22 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
EP1924567B1
(en)
|
2005-09-16 |
2012-08-22 |
Takeda Pharmaceutical Company Limited |
Process for the preparation of pyrimidinedione derivatives
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JOP20180109A1
(ar)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
CN101365476A
(zh)
*
|
2005-10-07 |
2009-02-11 |
瓦拉塔药品公司 |
Dpp-iv抑制剂和胃泌素化合物的联合使用
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
US20090054512A1
(en)
*
|
2006-01-06 |
2009-02-26 |
Foley James E |
Use of organic compounds
|
AU2007224066B2
(en)
|
2006-03-08 |
2011-10-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
BRPI0709894A2
(pt)
*
|
2006-04-03 |
2011-07-26 |
Matrix Lab Ltd |
inibidores de dipeptidil peptidase iv e processos para sua preparaÇço e composiÇço farmacÊuticas contendo-os
|
JP2009532454A
(ja)
*
|
2006-04-03 |
2009-09-10 |
マトリックス ラボラトリーズ リミテッド |
新規ジペプチジルペプチダーゼiv阻害因子およびその調製方法、ならび該阻害因子を含む医薬組成物
|
KR101281962B1
(ko)
|
2006-04-11 |
2013-07-08 |
아레나 파마슈티칼스, 인크. |
특정 개체에게서 골 질량을 증가시키는 데에 유용한 화합물을 확인하기 위해 gpr119 수용체를 사용하는 방법
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
AU2007267833B2
(en)
|
2006-05-26 |
2012-07-26 |
Amylin Pharmaceuticals, Llc |
Composition and methods for treatment of congestive heart failure
|
MEP8509A
(en)
|
2006-09-07 |
2011-12-20 |
|
Combination treatment for diabetes mellitus
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
AR062760A1
(es)
*
|
2006-09-13 |
2008-12-03 |
Takeda Pharmaceutical |
Administracion de inhibidores de dipeptidilpetidasa
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US20080167479A1
(en)
*
|
2007-01-10 |
2008-07-10 |
Medichem, S.A. |
Process for preparing vildagliptin
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
US8143427B2
(en)
*
|
2007-03-22 |
2012-03-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative
|
JP5616630B2
(ja)
|
2007-04-03 |
2014-10-29 |
田辺三菱製薬株式会社 |
ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用
|
DE102007022007A1
(de)
*
|
2007-05-08 |
2008-11-13 |
Schebo Biotech Ag |
Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
|
MX2009013354A
(es)
|
2007-06-04 |
2010-07-06 |
Univ Ben Gurion |
Compuestos de triarilo y composiciones que los contienen.
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
AU2008290582B2
(en)
*
|
2007-08-17 |
2014-08-14 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
GB2465132B
(en)
*
|
2007-09-21 |
2012-06-06 |
Lupin Ltd |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
US20090082420A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched vildagliptin
|
US8598314B2
(en)
*
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
RU2489439C2
(ru)
*
|
2007-11-30 |
2013-08-10 |
Новартис Аг |
Органические соединения
|
AU2008334444B2
(en)
|
2007-12-12 |
2011-12-15 |
Astrazeneca Ab |
Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors
|
AU2008341352B2
(en)
|
2007-12-21 |
2013-08-01 |
Lg Chem, Ltd. |
Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
PE20140960A1
(es)
*
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
WO2009155309A1
(en)
*
|
2008-06-19 |
2009-12-23 |
Concert Pharmaceuticals, Inc. |
Substituted cyanopyrrolidine derivatives
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
JP5476305B2
(ja)
*
|
2008-08-07 |
2014-04-23 |
杏林製薬株式会社 |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
WO2010018866A1
(ja)
*
|
2008-08-14 |
2010-02-18 |
杏林製薬株式会社 |
安定化された医薬組成物
|
CZ2008512A3
(cs)
*
|
2008-08-26 |
2010-03-10 |
Zentiva, A. S |
Zpusob prípravy vysoce cistého vildagliptinu
|
WO2010029089A2
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
CN102850330B
(zh)
*
|
2008-09-23 |
2014-10-15 |
成都地奥制药集团有限公司 |
经溴代的制备n取代的吡咯烷衍生物的方法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
WO2010072776A1
(en)
|
2008-12-23 |
2010-07-01 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
UY32048A
(es)
|
2009-01-08 |
2010-03-26 |
Boehringer Ingelheim Int |
Derivados sustituido de 1-(sustituido)-3-metil-7-(sustituido)-8-(3-(R)-amino-piperidin-1-il)cantina y derivados sustituidos de 1-(sustituido) - 4 - fluoropirrolidin- 2 - carbonitrilo y sus sales famacéuticamente aceptables como inhibidores de DPP-4 y aplicaciones.
|
CA2749301C
(en)
|
2009-01-09 |
2019-06-11 |
Gopalan Balasubramanian |
Dipeptidyl peptidase iv inhibitors
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
UA102429C2
(ru)
|
2009-02-13 |
2013-07-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
|
NZ619520A
(en)
|
2009-02-13 |
2015-06-26 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
EP2412370A4
(en)
|
2009-03-27 |
2013-05-22 |
Kyorin Seiyaku Kk |
MATRIX-LIKE EXTENDED RELEASE PREPARATION CONTAINING A BASIC ADDITIVE
|
CN102574830A
(zh)
|
2009-05-07 |
2012-07-11 |
阿斯利康(瑞典)有限公司 |
取代的1-氰基乙基杂环基甲酰胺化合物750
|
SI2429995T1
(sl)
|
2009-05-15 |
2014-05-30 |
Novartis Ag |
Arilpiridini kot inhibitorji aldosteron sintaze
|
KR20120036850A
(ko)
|
2009-05-15 |
2012-04-18 |
노파르티스 아게 |
알도스테론 신타제 억제제로서의 벤족사졸론 유도체
|
DK2435409T3
(da)
|
2009-05-28 |
2014-10-27 |
Novartis Ag |
Substituerede aminopropionsyrederivater som neprilysininhibitorer
|
EA201101672A1
(ru)
|
2009-05-28 |
2012-06-29 |
Новартис Аг |
Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
|
GB2483614B
(en)
|
2009-06-18 |
2014-12-03 |
Lupin Ltd |
2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
SI2459531T1
(sl)
|
2009-07-31 |
2020-02-28 |
Krka, D.D., Novo Mesto |
Granulat, ki obsega vildagliptin, in postopek njegove priprave
|
JP5734981B2
(ja)
|
2009-09-02 |
2015-06-17 |
メルク・シャープ・エンド・ドーム・コーポレイション |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼiv阻害剤としてのアミノテトラヒドロピラン
|
EA021275B9
(ru)
|
2009-09-03 |
2015-08-31 |
Байоэнердженикс |
Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
|
CA2774015A1
(en)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
A cdp-camptothecin conjugate, particle or composition and uses thereof
|
EP2295083A1
(de)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
|
HUP0900638A2
(en)
|
2009-10-07 |
2011-05-30 |
Egyt Gyogyszervegyeszeti Gyar |
Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
|
AU2010303780B2
(en)
|
2009-10-09 |
2014-02-20 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
EP2308847B1
(en)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
|
ES2663351T3
(es)
|
2009-11-17 |
2018-04-12 |
Novartis Ag |
Derivados de aril-piridina como inhibidores de la aldosterona sintasa
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
CN104208716A
(zh)
|
2009-11-23 |
2014-12-17 |
天蓝制药公司 |
用于传递治疗剂的基于环糊精的聚合物
|
CN102753161A
(zh)
|
2009-11-27 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
|
ES2472446T3
(es)
|
2009-11-30 |
2014-07-01 |
Novartis Ag |
Derivados de imidazol como inhibidores de aldosterona sintasa
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
JP5686413B2
(ja)
|
2009-12-22 |
2015-03-18 |
塩野義製薬株式会社 |
アダマンタンアミン誘導体
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
EP2538783B1
(en)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
CN101798270B
(zh)
*
|
2010-02-25 |
2013-04-17 |
东华大学 |
一种3-氨基-1-金刚烷醇的制备方法
|
WO2011113947A1
(en)
|
2010-03-18 |
2011-09-22 |
Boehringer Ingelheim International Gmbh |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
BR112012025592A2
(pt)
|
2010-04-06 |
2019-09-24 |
Arena Pharm Inc |
moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
WO2011146358A1
(en)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
CN101870671B
(zh)
*
|
2010-06-11 |
2012-06-27 |
漆又毛 |
金刚烷基吡咯烷衍生物及制备和应用
|
CN106975074A
(zh)
|
2010-06-24 |
2017-07-25 |
勃林格殷格翰国际有限公司 |
糖尿病治疗
|
IT1400714B1
(it)
|
2010-07-06 |
2013-06-28 |
Chemelectiva S R L |
Processo ed intermedi per la preparazione di un principio attivo.
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
CN103209957A
(zh)
*
|
2010-08-09 |
2013-07-17 |
盐野义制药株式会社 |
氨基金刚烷氨基甲酸酯衍生物的制备方法
|
HU231050B1
(hu)
|
2010-08-19 |
2020-02-28 |
Egis Gyógyszergyár Nyrt. |
Eljárás gyógyszerhatóanyag előállítására
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
EP2468268B1
(en)
|
2010-12-21 |
2017-12-13 |
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi |
Combination composition of vildagliptin and gliclazide
|
TR201107482A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San.Ve Ti̇c.A.Ş. |
Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
|
TR201101809A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ |
Vildagliptin ve glimepirid kombinasyonları.
|
TR201010683A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San. Ve Ti̇c. A.Ş. |
Vildagliptin formülasyonları.
|
NZ612804A
(en)
|
2011-01-31 |
2015-09-25 |
Cadila Healthcare Ltd |
Treatment for lipodystrophy
|
BR112013022147A2
(pt)
|
2011-03-02 |
2017-04-25 |
Bioenergenix |
composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2729468A4
(en)
|
2011-07-05 |
2015-03-18 |
Merck Sharp & Dohme |
TRICYCLIC HETEROCYCLES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
WO2013010964A1
(en)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
EP2753328A1
(en)
|
2011-09-07 |
2014-07-16 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dpp-iv inhibitor formulations
|
EP2572704A1
(en)
|
2011-09-22 |
2013-03-27 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally-Disintegrating Formulations of Vildagliptin
|
ES2487271T3
(es)
|
2011-10-06 |
2014-08-20 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulaciones de dosificación sólidas inhibidoras de DPP-IV
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
ITMI20112224A1
(it)
|
2011-12-06 |
2013-06-07 |
Chemelectiva S R L |
Nuovo processo ed intermedi per la sintesi di vildagliptin
|
CN102491928A
(zh)
*
|
2011-12-13 |
2012-06-13 |
临海天宇药业有限公司 |
一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
US9073930B2
(en)
|
2012-02-17 |
2015-07-07 |
Merck Sharp & Dohme |
Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
CN102617434B
(zh)
*
|
2012-03-29 |
2014-07-23 |
中国科学院上海有机化学研究所 |
一锅法制备维达列汀
|
WO2013179300A2
(en)
|
2012-05-04 |
2013-12-05 |
Megafine Pharma (P) Ltd. |
A process for the preparation of vildagliptin and its intermediate thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2014018350A1
(en)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-iv inhibitors
|
WO2014020462A1
(en)
*
|
2012-08-01 |
2014-02-06 |
Alembic Pharmaceuticals Limited |
Improved process for preparation of vildagliptin intermediate
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
CN103922986B
(zh)
*
|
2013-01-16 |
2017-02-15 |
上海彩迩文生化科技有限公司 |
维大列汀及其类似物、中间体及其制备方法和应用
|
HUE038248T2
(hu)
|
2013-02-14 |
2018-10-29 |
Novartis Ag |
Helyettesített biszfenil-bután-foszfonsav származékok, mint NEP (semleges endopeptidáz) inhibitorok
|
CN105377246B
(zh)
|
2013-04-22 |
2018-03-20 |
卡迪拉保健有限公司 |
针对非酒精性脂肪性肝病(nafld)的新组合物
|
US20160107989A1
(en)
|
2013-05-30 |
2016-04-21 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
CN103304502B
(zh)
*
|
2013-06-02 |
2015-03-04 |
张远强 |
一类抗糖尿病化合物、其制备方法和用途
|
TW201636015A
(zh)
|
2013-07-05 |
2016-10-16 |
卡地拉保健有限公司 |
協同性組成物
|
TN2016000031A1
(en)
|
2013-07-25 |
2017-07-05 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
IN2013MU02470A
(no)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
CN105705167A
(zh)
|
2013-07-25 |
2016-06-22 |
诺华股份有限公司 |
合成的apelin多肽的生物缀合物
|
WO2015033357A2
(en)
|
2013-09-06 |
2015-03-12 |
Cadila Healthcare Limited |
An improved process for the preparation of pyrrole derivatives
|
WO2015068156A1
(en)
|
2013-11-05 |
2015-05-14 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
CN103641761A
(zh)
*
|
2013-11-22 |
2014-03-19 |
沈阳化工大学 |
一种维格利汀的制备方法
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
US20170014380A1
(en)
|
2014-03-06 |
2017-01-19 |
Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi |
Vildagliptin Formulation Process Under Inert Gas Atmosphere
|
CN103992257B
(zh)
*
|
2014-05-16 |
2016-03-30 |
苏州天马精细化学品股份有限公司 |
一种维格列汀粗品的纯化方法
|
CN105439873A
(zh)
*
|
2014-08-20 |
2016-03-30 |
天津药物研究院 |
3-羟基-1-金刚烷胺的制备方法
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
CN105884669B
(zh)
*
|
2014-09-15 |
2020-05-15 |
深圳翰宇药业股份有限公司 |
制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
CN104529857B
(zh)
*
|
2015-01-13 |
2016-03-30 |
佛山市赛维斯医药科技有限公司 |
卤代金刚烷酰胺类衍生物、其制备方法和用途
|
CN107406490A
(zh)
|
2015-01-23 |
2017-11-28 |
诺华股份有限公司 |
具有改善的半衰期的合成apelin脂肪酸缀合物
|
KR20180006881A
(ko)
|
2015-03-09 |
2018-01-19 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
CN104761456B
(zh)
*
|
2015-03-10 |
2020-04-10 |
上海威智医药科技有限公司 |
3-氨基-1-金刚烷醇的制备方法
|
CN104817482B
(zh)
*
|
2015-03-17 |
2017-05-10 |
宁波百思佳医药科技有限公司 |
2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
|
PL3310760T3
(pl)
|
2015-06-22 |
2023-03-06 |
Arena Pharmaceuticals, Inc. |
Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
RU2628573C2
(ru)
*
|
2015-11-27 |
2017-08-21 |
Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" |
Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа
|
BR112018013195A2
(pt)
|
2015-12-28 |
2018-12-11 |
Wockhardt Ltd |
composição farmacêutica osmótica oral de vildagliptina
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
DE102016116130A1
(de)
|
2016-08-30 |
2018-03-01 |
Universität Bielefeld |
Verfahren zur Herstellung chiraler Aminonitrile
|
WO2018050892A1
(en)
|
2016-09-16 |
2018-03-22 |
Galenicum Health S.L. |
Vildagliptin pharmaceutical compositions
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
WO2018104916A1
(en)
|
2016-12-09 |
2018-06-14 |
Cadila Healthcare Limited |
Treatment for primary biliary cholangitis
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのPPARγアゴニスト
|
GR1009406B
(el)
|
2017-10-03 |
2018-11-26 |
Φαρματεν Αβεε |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
KR102622198B1
(ko)
|
2018-03-30 |
2024-01-09 |
한미약품 주식회사 |
빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
|
GR1009644B
(el)
|
2018-09-25 |
2019-11-12 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
JP2022509184A
(ja)
|
2018-11-27 |
2022-01-20 |
ノバルティス アーゲー |
代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
|
CN113166101A
(zh)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状五聚体化合物
|
JP7461735B2
(ja)
*
|
2019-12-02 |
2024-04-04 |
日本ジェネリック株式会社 |
ビルダグリプチン含有錠剤
|
CN113527167B
(zh)
*
|
2020-04-14 |
2024-01-19 |
威智医药股份有限公司 |
一种维格列汀的生产方法
|
WO2021234430A1
(en)
|
2020-05-17 |
2021-11-25 |
Lotus International Pte. Ltd. |
Modified release dosage form comprising vildagliptin and process for manufacturing the same
|
WO2022003405A1
(en)
|
2020-07-03 |
2022-01-06 |
Savoi Guilherme |
One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022159955A1
(en)
*
|
2021-01-21 |
2022-07-28 |
The Scripps Research Institute |
Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases
|
TW202333563A
(zh)
|
2021-11-12 |
2023-09-01 |
瑞士商諾華公司 |
用於治療疾病或障礙之二胺基環戊基吡啶衍生物
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|